Revive Therapeutics Looks To Bring Bucillamine To India
Revive Therapeutics (CSE: RVV) is looking to India. The company this morning indicated that it has entered into a memorandum of understanding with that of Supriya Lifescience to bring Bucillamine to the country under an emergency use authorization to treat COVID-19.
The arrangement will see Supriya, whom is a specialty pharma firm within India, work with Revive to pursue the manufacturing of the API, conduct clinical registration, and commercialize Bucillamine in the treatment of mild-to-moderate COVID-19 in India. Supriya is an EUGMP and USFDA approved manufacturer and supplier of active pharmaceutical products and ingredients, with exports to 78 separate countries.
The arrangement could also potentially lead to global commercialization of the drug, through the use of Supriya’s extensive manufacturing and commercial network in combination with the firms FDA phase 3 clinical trials. The firms manufacturing facilities are currently approved by over nine international regulatory authorities.
“While our Phase 3 clinical study for COVID-19 is ongoing in the USA, we are laying the ground work by partnering with Supriya to execute on our global manufacturing and commercialization plans and leveraging their regulatory expertise and commercial reach with 78 countries they currently supply pharmaceutical products to. We are focused on completing our current Phase 3 study in the USA and also obtaining EUA. These results will support drug approval registrations globally, including India, Europe, and Canada.”
Michael Frank, CEO of Revive
Revive Therapeutics last traded at $0.425 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
